GEN Exclusives

More »
Readers Comments Back to Item »

BAC Targeting Biosimilar Market

1 Readers' Comments

Posted by: Lester Savit


In October a federal court blocked market entry of a generic version of a complex active ingredient because of a patent on manufacturing (quality) control.  See for a discussion of how this ruling reveals a new patent strategy for biosimilars.

  • Click here to Login or to Register for free.

    You will be taken back to your selected item after Login/Registration.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »